PT Hisamitsu Pharma Indonesia is the Indonesian subsidiary of Japan's Hisamitsu Pharmaceutical Co., Inc. Established in 1975 as PT Salonpas Indonesia and renamed to its current name in 2003, the company operates a manufacturing facility in Sidoarjo, East Java. It is a market-leading manufacturer of topical analgesic products and fever compress patches in Indonesia, with its flagship brands Salonpas and ByeBye-FEVER recognized as top-of-mind icons in the country. The company received Good Manufacturing Practice (GMP) certification for its factory in 1996, 2003, and 2015, and its Salonpas brand has been named the world's No. 1 OTC topical analgesic patch brand for multiple consecutive years based on Euromonitor International research.
| Import | Export |
|---|---|
|
Trade Records
252
|
Trade Records
39
|
|
Suppliers
3
|
Buyers
4
|
|
Latest Import Date
2026-07
|
Latest Export Date
2026-07
|
According to Topease's global trade data, PT. HISAMITSU PHARMA INDONESIA exports products to verified importers across global markets.
Its export activity is associated with HS-code categories such as:
Representative importers include:
These export insights help users understand the PT. HISAMITSU PHARMA INDONESIA distribution footprint, product specialization, and shipment scale. Through Topease's deep trade data and trade intelligence capabilities—such as trade flow analysis and market benchmarking—importers and exporters can evaluate downstream demand and identify potential importer relationships.
As an importer, PT. HISAMITSU PHARMA INDONESIA sources products from verified exporters across multiple regions.
Its import activity spans HS-code categories including:
Representative exporters include:
These import insights help users assess sourcing patterns, supplier concentration, and trade continuity. With Topease's analytical tools—such as sourcing pattern analysis and supply-chain mapping—users can evaluate supplier performance and identify diversification opportunities.
Explore PT. HISAMITSU PHARMA INDONESIA's import activity, including trade volumes, top suppliers, sourcing countries, and key product categories. These insights allow exporters and potential suppliers to understand its global supply chains, track procurement trends, and identify new business opportunities.
| Exporter | Importer | HS Code | Number of Trade | Amount (USD) | Quantity | Import Port |
|---|---|---|---|---|---|---|
| HISAMITSU PHARMACEUTICAL CO. INC. | PT. HISAMITSU PHARMA INDONESIA | 2833 | 24 | $186,500 | 3,420 | Los Angeles |
| FUJI ENGINEERING INC | PT. HISAMITSU PHARMA INDONESIA | 8451 | 24 | $186,500 | 3,420 | Los Angeles |
| NANYO CO LTD | PT. HISAMITSU PHARMA INDONESIA | 8537 | 24 | $186,500 | 3,420 | Los Angeles |
Gain insights into PT. HISAMITSU PHARMA INDONESIA's export activities, including shipment volumes, key buyers, destination countries, and product categories. Understand global demand patterns, track sales reach, and spot opportunities to connect with potential buyers.
| Importer | Exporter | HS Code | Number of Trade | Amount (USD) | Quantity | Export Port |
|---|---|---|---|---|---|---|
| MONTANA MARKETING CO LTD | PT. HISAMITSU PHARMA INDONESIA | 3004 | 24 | $186,500 | 3,420 | Los Angeles |
| HISAMITSU PHARMACEUTICAL CO. INC. | PT. HISAMITSU PHARMA INDONESIA | 3004 | 24 | $186,500 | 3,420 | Los Angeles |
| PETER'S ENTERPRISE LTD | PT. HISAMITSU PHARMA INDONESIA | 3004 | 24 | $186,500 | 3,420 | Los Angeles |
| AL-MOJIL DRUG COMPANY K S C C | PT. HISAMITSU PHARMA INDONESIA | 3004 | 24 | $186,500 | 3,420 | Los Angeles |
Chain Insights — Explore PT. HISAMITSU PHARMA INDONESIA's trading network to uncover connections with international buyers and suppliers. With Topease's Supply Chain Solution, you can track product flows and identify patterns that reveal new sourcing and partnership opportunities.
Access PT. HISAMITSU PHARMA INDONESIA's key professional contacts for B2B outreach purposes. View verified phone numbers, emails, and LinkedIn profiles to facilitate efficient business communication.
Disclaimer: Data is compiled from public and third-party sources and may not be complete or fully accurate. This information is provided for business intelligence purposes only and should not be used for legal, financial, or compliance decisions.